Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Wave Life Sciences Ltd. (WVE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Investor presentation, Quarterly results
Docs: "Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update",
"Corporate Presentation of Wave Life Sciences Ltd."
05/23/2023 8-K Investor presentation
Docs: "Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia",
"Corporate Presentation of Wave Life Sciences Ltd."
05/03/2023 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update",
"Corporate Presentation of Wave Life Sciences Ltd."
01/09/2023 8-K Investor presentation
Docs: "Investor Presentation of Wave Life Sciences Ltd."
11/15/2022 8-K Quarterly results
10/04/2022 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd.",
"Corporate Presentation of Wave Life Sciences Ltd."
08/17/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
01/10/2022 8-K Investor presentation
Docs: "Investor Presentation of Wave Life Sciences Ltd."
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update",
"Corporate Presentation of Wave Life Sciences Ltd."
09/28/2021 8-K Investor presentation
Docs: "Analyst & Investor Research Webcast for Wave Life Sciences Ltd.",
"Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast"
09/10/2021 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd.",
"Corporate Presentation of Wave Life Sciences Ltd."
04/01/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/12/2020 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd."
10/01/2020 8-K Quarterly results
09/09/2020 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd.",
"Corporate Presentation of Wave Life Sciences Ltd."
08/25/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
01/13/2020 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd."
12/30/2019 8-K Quarterly results
12/16/2019 8-K Investor presentation
Docs: "Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy",
"Corporate Presentation of Wave Life Sciences Ltd."
11/05/2019 8-K Investor presentation, Quarterly results
Docs: "Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update",
"Corporate Presentation of Wave Life Sciences Ltd."
10/07/2019 8-K Quarterly results
07/29/2019 8-K Quarterly results
06/05/2019 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd.",
"Corporate Presentation of Wave Life Sciences Ltd."
05/10/2019 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 10, 2019 WAVE LIFE SCIENCES LTD. Singapore 001-37627 Not Applicable 7 Straits View #12-00, Marina One East Tower Singapore 018936 018936 Registrant's telephone number, including area code: +65 6236 3388 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act...",
"Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update",
"Corporate Presentation of Wave Life Sciences Ltd."
04/16/2019 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : April 16, 2019 WAVE LIFE SCIENCES LTD. Singapore 001-37627 Not Applicable 7 Straits View #12-00, Marina One East Tower Singapore 018936 018936 Registrant's telephone number, including area code: +65 6236 3388 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Ac...",
"Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design",
"Investor Slide Presentation"
03/01/2019 8-K Quarterly results
01/03/2019 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd.",
"Corporate Presentation of Wave Life Sciences Ltd."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy